Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.89 USD
Change Today -0.1262 / -6.25%
Volume 50.2K
As of 1:27 PM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

celgene corp-cvr (CELGZ) Snapshot

Open
$2.00
Previous Close
$2.02
Day High
$2.00
Day Low
$1.85
52 Week High
10/1/14 - $3.83
52 Week Low
08/4/15 - $1.85
Market Cap
--
Average Volume 10 Days
17.4K
EPS TTM
--
Shares Outstanding
43.0M
EX-Date
10/8/13
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CELGENE CORP-CVR (CELGZ)

celgene corp-cvr (CELGZ) Related Businessweek News

View More BusinessWeek News

celgene corp-cvr (CELGZ) Details

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers; POMALYST/IMNOVID for the treatment of multiple myeloma; and VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML). The company’s products also include THALOMID for the patients with multiple myeloma and for the treatment of cutaneous manifestations of erythema nodosum leprosum; OTEZLA for psoriatic arthritis, psoriasis, and ankylosing spondylitis; ISTODAX to treat cutaneous and peripheral T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN LA products. Its clinical stage products comprise oral anti-inflammatory agents targeting PDE4, an intracellular enzyme that modulates the production of multiple pro-inflammatory and anti-inflammatory mediators; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; cellular therapies, such as PDA-001 and PDA-002 for Crohn’s and peripheral arterial diseases; CC-486 to treat MDS, AML, and solid tumors; Sotatercept and luspatercept for the treatment of anemia; and CC-223 and CC-115 for lymphomas, hepatocellular, and prostate cancers. The company has collaborative agreements with Novartis Pharma AG; Acceleron Pharma; Agios Pharmaceuticals, Inc.; Epizyme Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; MorphoSys AG; Acetylon Pharmaceuticals, Inc.; OncoMed Pharmaceuticals, Inc.; and NantBioScience, Inc. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.

6,012 Employees
Last Reported Date: 02/20/15
Founded in 1980

celgene corp-cvr (CELGZ) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.4M
President and Chief Operating Officer
Total Annual Compensation: $767.9K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $400.0K
Chief Executive Officer of Celgene Cellular T...
Total Annual Compensation: $666.5K
President of Global Hematology and Oncology
Total Annual Compensation: $803.3K
Compensation as of Fiscal Year 2014.

celgene corp-cvr (CELGZ) Key Developments

Bionor Pharma ASA Enters into Supply Agreement with Celgene Corporation

Bionor Pharma ASA has signed an agreement with Celgene Corporation (Celgene) securing a continued supply of romidepsin (Istodax) for use in a planned multicenter clinical Phase II study of Bionor's most advanced and proprietary vaccine, Vacc-4x, with romidepsin. The planned study will continue to explore the ‘Kick and Kill’ strategy of Bionor's ongoing REDUC study, for which Celgene also supplies romidepsin. In Part A of the REDUC study, completed in 2014, it was demonstrated that romidepsin was safe, well tolerated and able to release HIV viral DNA from latent reservoirs into the blood stream in HIV infected patients on anti-retroviral treatment. An interim analysis of Part B of the REDUC study announced on 4 May 2015 indicated killing of reactivated HIV and reduction in latent viral reservoir when patients received Vacc-4x prior to romidepsin.

Bionor Pharma ASA Signs Agreement with Celgene Corporation for Supply of Romidepsin

Bionor Pharma ASA signed an agreement with Celgene Corporation (Celgene) securing a continued supply of romidepsin (Istodax) for use in a planned multicenter clinical Phase II study of Bionor’s Vacc-4x, with romidepsin. The planned study will continue to explore the ‘Kick and Kill’ strategy of Bionor’s ongoing REDUC study, for which Celgene also supplies romidepsin. In Part A of the REDUC study, completed in 2014, it was demonstrated that romidepsin was safe, well tolerated and able to release HIV viral DNA from latent reservoirs into the blood stream in HIV infected patients on anti-retroviral treatment. An interim analysis of Part B of the REDUC study announced on 4 May 2015 indicated killing of reactivated HIV and reduction in latent viral reservoir when patients received Vacc-4x prior to romidepsin.

Celgene Corporation Reports Preliminary Earnings Results for the Second Quarter of 2015; Revises Earnings Guidance for the Full Year 2015

Celgene Corporation reported preliminary earnings results for the second quarter of 2015. For the period, the company reported preliminary net product sales of $2,254 million compared to $1,845 million in the second quarter of 2014, represents an increase of 22%. Second quarter total revenue also increased 22% to approximately $2,278 million compared to $1,873 million in the second quarter of 2014. For the same period, adjusted diluted EPS increased 37% to approximately $1.23 from $0.90. Adjusted diluted EPS for the second quarter of 2015 included a $0.06 per share gain related to the sale of an equity investment upon the completion of their acquisition by another company. Based on U.S. GAAP (Generally Accepted Accounting Principles), preliminary second quarter 2015 diluted EPS was approximately $0.43 per diluted share. For the second quarter of 2014, diluted EPS was $0.72 per diluted share. Second quarter 2015 GAAP EPS included increased expenses for upfront collaboration payments. For 2015, the company re-affirming total net product sales to a range of $9 billion to $9.5 billion. The company is raising adjusted diluted EPS to a range of $4.75 to $4.85 from the previous range of $4.60 to $4.75, an increase of approximately 29% over 2014 adjusted diluted EPS. GAAP diluted EPS is expected to be in the range of $2.43 to $2.71 from the previous range of $2.97 to $3.19. Adjusted diluted EPS is expected to exceed $13.00, up from the previous target of $12.50.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CELGZ:US $1.89 USD -0.1262

CELGZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan plc $335.59 USD +0.67
Biogen Inc $333.78 USD +9.40
Bristol-Myers Squibb Co $65.07 USD -0.27
Medtronic PLC $77.97 USD -0.03
Valeant Pharmaceuticals International Inc C$341.29 CAD +5.68
View Industry Companies
 

Industry Analysis

CELGZ

Industry Average

Valuation CELGZ Industry Range
Price/Earnings 49.7x
Price/Sales 12.4x
Price/Book 16.4x
Price/Cash Flow 42.3x
TEV/Sales 10.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELGENE CORP-CVR, please visit www.celgene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.